139 related articles for article (PubMed ID: 21278444)
21. Adjuvant chemotherapy for early-stage breast cancer.
McArthur HL; Hudis CA
Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
[TBL] [Abstract][Full Text] [Related]
22. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
[TBL] [Abstract][Full Text] [Related]
23. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
Venkitaraman R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
25. Special issues related to breast cancer adjuvant therapy in older women.
Witherby SM; Muss HB
Breast; 2005 Dec; 14(6):600-11. PubMed ID: 16198568
[TBL] [Abstract][Full Text] [Related]
26. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
[TBL] [Abstract][Full Text] [Related]
27. Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls.
Barni S; Cabiddu M; Petrelli F
Expert Rev Anticancer Ther; 2010 Feb; 10(2):185-98. PubMed ID: 20131995
[TBL] [Abstract][Full Text] [Related]
28. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
Kasami M; Uematsu T; Honda M; Yabuzaki T; Sanuki J; Uchida Y; Sugimura H
Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
[TBL] [Abstract][Full Text] [Related]
29. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
30. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
32. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the use of anthracyclines in older patients with breast cancer.
Morris PG; Fornier MN
Crit Rev Oncol Hematol; 2011 Feb; 77(2):131-41. PubMed ID: 20227291
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer in older women.
Muss HB
Semin Oncol; 1996 Feb; 23(1 Suppl 2):82-8. PubMed ID: 8614851
[TBL] [Abstract][Full Text] [Related]
35. New developments in hormone receptor-positive disease.
Piccart-Gebhart MJ
Oncologist; 2011; 16 Suppl 1():40-50. PubMed ID: 21278440
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
Hurria A; Naeim A; Elkin E; Limaye S; Grover A; Hudis C; Pearce C; Robson M
Crit Rev Oncol Hematol; 2007 Mar; 61(3):255-60. PubMed ID: 17098441
[TBL] [Abstract][Full Text] [Related]
37. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
Voduc D; Nielsen TO
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
[TBL] [Abstract][Full Text] [Related]
38. NCCN Task Force Report: breast cancer in the older woman.
Carlson RW; Moench S; Hurria A; Balducci L; Burstein HJ; Goldstein LJ; Gradishar WJ; Hughes KS; Jahanzeb M; Lichtman SM; Marks LB; McClure JS; McCormick B; Nabell LM; Pierce LJ; Smith ML; Topham NS; Traina TA; Ward JH; Winer EP
J Natl Compr Canc Netw; 2008; 6 Suppl 4():S1-25; quiz S26-7. PubMed ID: 18597715
[TBL] [Abstract][Full Text] [Related]
39. Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?
Chiuri VE; Lorusso V
Oncology; 2009; 77 Suppl 1():18-22. PubMed ID: 20130428
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
Kennedy CR; Gao F; Margenthaler JA
J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
